|Bid||96.06 x 1400|
|Ask||96.07 x 1200|
|Day's Range||95.75 - 96.33|
|52 Week Range||58.59 - 97.07|
|Beta (3Y Monthly)||2.01|
|PE Ratio (TTM)||14.62|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||97.00|
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
For these mental hacks, David Gardner tapped the wisdom of four authors and one alien hive mind. For the stocks, he looked to the Information Age for inspiration.
Celgene Corporation (CELG) and the Multiple Sclerosis Association of America (MSAA) today announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can do to keep their brain as healthy as possible, for as long as possible. To bring this new perspective on MS closer to the community, the campaign will host engaging, educational events in various cities.
While value investors continue to read through Seth Klarman (Trades, Portfolio)'s most recent partnership letter, others are tracking his latest filings to see what the guru has deemed worthy of buying. Warning! GuruFocus has detected 3 Warning Sign with CDAY.
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
The latest round of 13F filings from institutional investors were out this week, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling. Takeaways ...
Carlson Capital is a Dallas, Texas-based multi-strategy alternative hedge fund that provides additional offices in Houston, New York City, Palm Beach Gardens, Greenwich, and London. It was founded by Clint Carlson back in 1993 and grew big since then, now managing more than $7 billion in hedge fund and CLO assets. Prior to launching his […]
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
The European Commission has approved two of Celgene’s IMiD®-based combination regimens:
Adage Capital Management is a Boston-based hedge fund, launched by Phil Gross and Robert Atchinson back in 2001. Both Phil Gross and Robert Atchinson previously worked at Harvard University’s endowment, and their team managed to beat the S&P 500 Index by an average of 4.5 percentage points annually. Considering this success, it comes as no […]
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
Bristol-Myers Squibb's (BMY) move to raise close to $20 billion in debt to acquire Celgene (CELG) looks dangerous, but years from now it may be considered a savvy move. True, the huge aggregate number of $58 billion in combined debt between the two companies certainly doesn't look all that flattering, especially in the context of threats by all three credit rating agencies - Moody's, Fitch and S&P Global Ratings - to downgrade the company's credit rating. The ratings agencies correctly cite total debt at 4x earnings, and that makes the corporate bond markets justifiably jittery.